Loading...Loading...In the latest quarter, 9 analysts provided ratings for GE HealthCare Techs GEHC, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months..

正在加载。。。正在加载。。。在最近一个季度，9位分析师为GE HealthCare Techs GEHC提供了评级，显示出看涨和看跌的观点。下表概括了他们最近的评级，简要介绍了过去30天的情绪变化，并将其与前几个月进行了比较。。

Bullish

看涨

Somewhat Bullish

有点看涨

Indifferent

漠不关心

Somewhat Bearish

有点看空

Bearish

看跌

Total Ratings

总评级

6

6

1

1

2

2

0

0

0

0

Last 30D

最近30天

1

1

0

0

0

0

0

0

0

0

1M Ago

100万年前

3

3

1

1

0

0

0

0

0

0

2M Ago

200万年前

0

0

0

0

0

0

0

0

0

0

3M Ago

300万年前

2

2

0

0

2

2

0

0

0

0

Analysts have recently evaluated GE HealthCare Techs and provided 12-month price targets. The average target is $99.78, accompanied by a high estimate of $110.00 and a low estimate of $86.00. Marking an increase of 13.88%, the current average surpasses the previous average price target of $87.62. Exploring Analyst Ratings: An In-Depth OverviewA comprehensive examination of how financial experts perceive GE HealthCare Techs is derived from recent analyst actions.

分析师最近对GE HealthCare Techs进行了评估，并提供了12个月的价格目标。平均目标为99.78美元，高估计为110.00美元，低估计为86.00美元。目前的平均价格比之前87.62美元的平均价格目标高出13.88%。探索分析师评级：深入概述财务专家如何看待GE HealthCare技术的全面检查来自最近的分析师行动。

The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets..

以下是主要分析师的详细总结，他们最近的评估以及对评级和价格目标的调整。。

Analyst

分析员

Analyst Firm

分析公司

Action Taken

采取行动

Rating

评级

Current Price Target

当前价格目标

Prior Price Target

先前价格目标

Anthony Petrone

安东尼·彼得龙

Mizuho

瑞穗

Lowers

降低

Buy

购买

$105.00

$105.00

$110.00

$110.00

Anthony Petrone

安东尼·彼得龙

Mizuho

瑞穗

Raises

提高

Buy

购买

$110.00

$110.00

$96.00

$96.00

Vijay Kumar

Vijay Kumar

Evercore ISI Group

Evercore ISI集团

Raises

提高

Outperform

表现优异

$100.00

$100.00

$93.00

$93.00

Joanne Wuensch

乔安妮·旺斯

Citigroup

花旗集团

Raises

提高

Buy

购买

$103.00

$103.00

$88.00

$88.00

David Toung

David Toung

Argus Research

阿格斯研究

Raises

提高

Buy

购买

$110.00

$110.00

$80.00

$80.00

Sezgi Oezener

Sezgi Oezener

HSBC

汇丰银行

Announces

宣布

Buy

购买

$100.00

$100.00

-

-（笑声）

Patrick Wood

帕特里克·伍德

Morgan Stanley

摩根士丹利

Raises

提高

Equal-Weight

同等重量

$86.00

$86.00

$74.00

$74.00

Graham Doyle

Graham Doyle

UBS

瑞士联合银行

Raises

提高

Neutral

中立

$88.00

$88.00

$66.00

$66.00

Anthony Petrone

安东尼·彼得龙

Mizuho

瑞穗

Raises

提高

Buy

购买

$96.00

$96.00

$94.00

$94.00

Key Insights:Loading...Loading...

关键见解：加载。。。正在加载。。。

Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GE HealthCare Techs. This information provides a snapshot of how analysts perceive the current state of the company..

采取的行动：分析师经常根据不断变化的市场状况和公司业绩更新他们的建议。无论他们是“维持”、“提高”还是“降低”自己的立场，这都反映了他们对与GE医疗保健技术相关的最新发展的反应。这些信息提供了分析师如何看待公司现状的快照。。

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of GE HealthCare Techs compared to the broader market.

评级：分析师深入评估，从“表现优异”到“表现不佳”分配定性值。这些评级传达了对GE HealthCare技术相对于更广泛市场的相对表现的期望。

Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of GE HealthCare Techs's stock. This examination reveals shifts in analysts' expectations over time.

价格目标：分析师探索价格目标的动态，为GE HealthCare Techs股票的未来价值提供估计。这项检查揭示了分析师的预期随着时间的推移而发生的变化。

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GE HealthCare Techs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.Stay up to date on GE HealthCare Techs analyst ratings.All You Need to Know About GE HealthCare TechsGE HealthCare Technologies Inc is a globally medical technology, pharmaceutical diagnostics, and digital solutions innovator company.

分析这些分析师评估以及相关财务指标可以全面了解GE HealthCare Techs的市场地位。在评级表的帮助下，随时了解情况并做出数据驱动的决策。了解GE HealthCare Techs分析师评级的最新信息。您只需要了解GE HealthCare TechsGE HealthCare Technologies Inc，它是一家全球性的医疗技术、药物诊断和数字解决方案创新公司。

It has four operating segments; Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). It earns a majority of its revenue from the Imaging segment.Understanding the Numbers: GE HealthCare Techs's FinancesMarket Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.Revenue Growth: GE HealthCare Techs displayed positive results in 3 months.

它有四个运营部门；成像，超声波，患者护理解决方案（PCS）和药物诊断（PDx）。它的大部分收入来自成像部门。了解数字：GE HealthCare Techs的金融市场资本化：该公司的市值高于行业平均水平，突显了其规模优势，表明其强大的市场占有率。收入增长：GE HealthCare Techs在3个月内取得了积极成果。

As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 5.43%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.Net Margin: GE HealthCare Techs's net margin falls below industry averages, indicating challenges in achieving strong profitability.

截至2023年12月31日，该公司实现了约5.43%的稳定收入增长率。这表明该公司的盈利显著增加。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。净利润率：GE HealthCare Techs的净利润率低于行业平均水平，表明在实现强劲盈利能力方面存在挑战。

With a net margin of 7.74%, the company may face hurdles in effective cost management.Return on Equity (ROE): GE HealthCare Techs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.65% ROE, the company effectively utilizes shareholder equity capital.Return on Assets (ROA): GE HealthCare Techs's ROA lags behi.

由于净利润率为7.74%，该公司可能在有效的成本管理方面面临障碍。股本回报率（ROE）：GE HealthCare Techs的ROE超过了行业标准，突显了该公司出色的财务表现。凭借令人印象深刻的5.65%的净资产收益率，该公司有效地利用了股东权益资本。资产回报率（ROA）：GE HealthCare Techs的ROA落后于behi。